Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified. The big Swiss ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...

Novartis (NVS) announced that the Food and ... who have been treated with an androgen receptor pathway inhibitor therapy and are considered appropriate to delay chemotherapy.

Pharmaceutical company Novartis said it plans to expand U.S.-based manufacturing and research and development, with a total investment of $23 billion over the next five years.